Needle-free vaccine innovator banks $34m

Source: Australian Financial Review

06 December 2022

We couldn’t be happier to have been a part of the latest financing round for Vaxxas – a company that OneVentures has been supporting for a very long time, with good reason.

The development of the nanopatch to deliver needle-free vaccines has massive global potential. We are now witnessing the pivotal stages in the company’s development: an in-human clinical trial that is now actively recruiting and the commercialisation of production through building a new manufacturing centre in Brisbane.

It is extremely gratifying to see companies grow from early stages to being on the cusp of changing how vaccines are delivered around the world. Read the full article in the Australian Financial Review

Posted in — AFR

You may also like

22 March 2018

Reskilling in the modern age

30 November 2019

Shippit builds on partnerships

10 March 2014

Tech IPO market is ‘open’ in Australia: VC

07 July 2021

‘Just like Netflix’: Southern Cross backs AI start-up

05 March 2018

Telco OVO Mobile buys AI-driven NICTA media spinout Incoming Media

27 February 2013

Who’s disrupting your industry? Meet 10 start-ups eager to eat the big boys’ lunch

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor